RA-101348

N/A

Report date: 2022/07/01 15:29:28
NME

Base Information

Drug NameRA-101348
Drug Alias NameRA-101348
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionComplement C5 inhibitors
TargetsComplement C5
Therapy Area/IndicationsHemoglobinuria, ParoxysmalAtypical Hemolytic Uremic Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRa Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesRa Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsHemoglobinuria, ParoxysmalAtypical Hemolytic Uremic Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A